Journal of cardiothoracic and vascular anesthesia · 2026
Intravenous Esketamine Versus Erector Spinae Plane Block for Postoperative Recovery Quality Following Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Non-Inferiority Trial.
СтатьяРандомизированное исследованиеEquivalence TrialСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhi, Zhao Haishu, Ning Yao, Zhang Yue, Liu Mengna, Hui Kangli, Gao Dapeng, Ji Qing, Zhang Lidong
Аннотация
OBJECTIVES: This non-inferiority trial compared intravenous esketamine with erector spinae plane block (ESPB) for postoperative recovery quality and analgesic efficacy in patients undergoing video-assisted thoracoscopic surgery (VATS).
DESIGN: Randomized controlled non-inferiority study.
SETTING: Single-center, university hospital.
PARTICIPANTS: One hundred twelve patients undergoing VATS.
INTERVENTIONS: The esketamine group received intravenous esketamine (0.25-mg/kg bolus + 0.25-mg/kg/h infusion) combined with a sham ESPB (25 mL of saline solution). The ESPB group received active ESPB (25 mL of 0.375% ropivacaine) plus intravenous saline solution.
MEASUREMENTS AND MAIN RESULTS: Outcomes included 15-item quality of recovery (Quality of Recovery-15 [QoR-15]) scores, postoperative pain scores, Hospital Anxiety and Depression Scale (HADS) scores, and perioperative hemodynamic changes. The differences in the QoR-15 scores between the groups on postoperative day 1 (mean difference, 1.0; 95% confidence interval [CI], -2.9 to 4.8; p = 0.622) and postoperative day 2 (mean difference, 0.4; 95% CI, -3.4 to 4.3; p = 0.833) met the non-inferiority criterion (-6 points). The ESPB group showed significantly lower pain scores during coughing at 4 hours (p = 0.026) and 8 hours (p = 0.006) postoperatively. The esketamine group had lower HADS scores and a lower incidence of hypotension.
CONCLUSIONS: Intravenous esketamine provides postoperative recovery quality that is non-inferior to ESPB after VATS, primarily because of its beneficial effects on mood, which compensates for its weaker early analgesia. Thus, esketamine may serve not as a direct analgesic substitute for ESPB, but as a rescue option when ESPB is not feasible, or as an analgesic adjunct with anxiolytic and antidepressant effects.
DESIGN: Randomized controlled non-inferiority study.
SETTING: Single-center, university hospital.
PARTICIPANTS: One hundred twelve patients undergoing VATS.
INTERVENTIONS: The esketamine group received intravenous esketamine (0.25-mg/kg bolus + 0.25-mg/kg/h infusion) combined with a sham ESPB (25 mL of saline solution). The ESPB group received active ESPB (25 mL of 0.375% ropivacaine) plus intravenous saline solution.
MEASUREMENTS AND MAIN RESULTS: Outcomes included 15-item quality of recovery (Quality of Recovery-15 [QoR-15]) scores, postoperative pain scores, Hospital Anxiety and Depression Scale (HADS) scores, and perioperative hemodynamic changes. The differences in the QoR-15 scores between the groups on postoperative day 1 (mean difference, 1.0; 95% confidence interval [CI], -2.9 to 4.8; p = 0.622) and postoperative day 2 (mean difference, 0.4; 95% CI, -3.4 to 4.3; p = 0.833) met the non-inferiority criterion (-6 points). The ESPB group showed significantly lower pain scores during coughing at 4 hours (p = 0.026) and 8 hours (p = 0.006) postoperatively. The esketamine group had lower HADS scores and a lower incidence of hypotension.
CONCLUSIONS: Intravenous esketamine provides postoperative recovery quality that is non-inferior to ESPB after VATS, primarily because of its beneficial effects on mood, which compensates for its weaker early analgesia. Thus, esketamine may serve not as a direct analgesic substitute for ESPB, but as a rescue option when ESPB is not feasible, or as an analgesic adjunct with anxiolytic and antidepressant effects.